Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001212557 | SCV001384145 | likely benign | Jeune thoracic dystrophy; Nephronophthisis | 2024-11-11 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002497725 | SCV002782656 | uncertain significance | Asphyxiating thoracic dystrophy 4; Nephronophthisis 12 | 2021-09-27 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004538457 | SCV004120390 | uncertain significance | TTC21B-related disorder | 2022-12-19 | criteria provided, single submitter | clinical testing | The TTC21B c.913A>G variant is predicted to result in the amino acid substitution p.Ile305Val. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.12% of alleles in individuals of South Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-166786856-T-C). Although we suspect that this variant may be benign, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ambry Genetics | RCV004033859 | SCV004972701 | uncertain significance | Inborn genetic diseases | 2021-10-22 | criteria provided, single submitter | clinical testing | The c.913A>G (p.I305V) alteration is located in exon 9 (coding exon 9) of the TTC21B gene. This alteration results from a A to G substitution at nucleotide position 913, causing the isoleucine (I) at amino acid position 305 to be replaced by a valine (V). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |